Rebif 22 micrograms/0.5 mL solution for injection in cartridge
Authorisation EU/1/98/063/008,18 · Merck Europe B.V.
- Licence holder
- Merck Europe B.V. (all products →)
- Active substance
- Interferon beta-1-a
- Dosage form
- Solution for injection in cartridge
- Route of administration
- Subcutaneous use
- ATC codes
- L03AB, L03AB07
- First authorised
- 16/01/2009
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Interferon beta-1-a: supply and approvals
3 authorised products on the HPRA list contain Interferon beta-1-a. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 063. It has been authorised for 17 years (since 16 January 2009). The HPRA list does not say whether it is on sale.
Other medicines with Interferon beta-1-a in Ireland
2 other products on the HPRA list contain Interferon beta-1-a, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Rebif 44 micrograms/0.5 mL solution for injection in cartridge | Merck Europe B.V. | Centralised EU authorisation | Not stated |
| Rebif 8.8 micrograms/0.1 mL + 22 micrograms/0.25 mL solution for injection in cartridge Initiation pack | Merck Europe B.V. | Centralised EU authorisation | Not stated |
Other substances in ATC group L03AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 3 other active substances share the group L03AB with this product:
Interferon beta - 1a (9) · Peginterferon-alfa-2a (3) · Interferon beta-1b (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Merck Europe B.V. holds 39 products on the HPRA list, with 12 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.